Clinical Trial

Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2025 (before its estimated August 16, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study, the investigators provide an individualized tumor neoantigen peptide vaccine in combination with radiotherapy to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the individualized tumor neoantigen peptide vaccine in combination with radiotherapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-10.
Status change: Not Yet Recruiting → Recruiting 2025-03-19
Trial Details
NCT Number NCT06314087
Lead Sponsor The University of Hong Kong-Shenzhen Hospital
Conditions Advanced Tumors
Enrollment 154 participants
Start Date 2024-01-31
Primary Completion 2026-08-16 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-25